12 results about "Lean body mass" patented technology

The invention discloses lactobacillus delbrueckii with a muscle protection function in a fat reducing period as well as a product and application thereof, belongs to the technical field of microorganisms, and discloses lactobacillus delbrueckii subsp. Lactis Turb8 with the preservation number of CGMCC No.35627. The lactobacillus delbrueckii subsp. Lactis Turb8 has the advantages that the preservation number is CGMCC No.35627; the strain or the preparation thereof can effectively prevent or improve the accompanying problems of muscle loss and function decline in the process of applying fat-reducing drugs such as GLP-1 receptor agonists (such as liraglutide and semeglutide), and the effect of reducing fat but not reducing muscle is achieved. The strain disclosed by the invention can be used for remarkably increasing the lean body mass ratio of a user, increasing the muscle mass of lower limbs, increasing the cross sectional area of muscle fibers and improving muscle function indexes such as strength of four limbs and suspension endurance while keeping the original weight-reducing effect of a fat-reducing medicine. The invention also relates to microbial agents comprising this strain, various preparations, their use in the preparation of products for ameliorating (in particular drug-induced) muscle reduction.

This invention relates to the field of functional food technology, and discloses a muscle-building, lipid-lowering, and weight-loss composition, its preparation method, and its application. The composition, by weight, comprises: 25-45 parts of complex protein peptides; 5-20 parts of fruit and vegetable powder; 2-8 parts of medicinal and edible extracts; 3-12 parts of complex prebiotics; 1-6 parts of complex vitamins and minerals; 0.5-3 parts of probiotics; 0.5-5 parts of calcium β-hydroxy-β-methylbutyrate; and the remainder being food-acceptable excipients. This invention achieves significant lipid-lowering and weight-loss while effectively increasing lean body mass and muscle mass, and the active ingredients exhibit good stability.

The present invention relates to the use of an s100a8 / a9 and complement 3 inhibitor in the preparation of a drug for treating or preventing cachexia. The treatment or prevention of cachexia comprises increasing the body weight, lean body mass and fat mass, and increasing food intake in a cachectic subject, or preventing fat mass consumption, slowing the rate of body weight loss, the rate of fat mass loss and the rate of lean body mass loss, counteracting anorexia, muscle strength loss, fatigue and body weight loss, or improving abnormal biochemical results. Provided is a new understanding for the mechanism of energy balance regulation in cancer cachexia, with an emphasis on the effects of S100a8 / a9 and C3 in cancer cachexia. The inhibition of S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. Particularly, it is verified that an S100a8 / a9 inhibitor can prevent body weight loss, especially adipose tissue loss, in a cachectic subject, and significantly increases food intake in the subject.

The present invention provides a body composition estimation program and information processing device that estimate body composition based on measurable values ​​without invasiveness. [Solution] Terminal 1 includes a lean body mass estimation means for estimating lean body mass based on the user's age, gender, height, and weight; a muscle mass estimation means for estimating muscle mass based on the user's age, gender, height, and weight; a sarcopenia determination means for determining the likelihood of sarcopenia based on at least one of lean body mass and muscle mass; a survival rate evaluation means 104 for evaluating the survival rate based on at least one of lean body mass and muscle mass; and a standard index calculation means 105 for calculating a standard index for insurance enrollment based on at least one of lean body mass and muscle mass.

The present invention relates to an immunogenic compound comprising an ApoB100 epitope, an immunogenic composition comprising the same, and uses thereof. The immunogenic compound can be used to prevent or treat diseases caused by increased ApoB100 levels or increased lipid levels by inducing an immune response to the ApoB100 epitope. The immunogenic compound has a complementary mechanism to GIP-1R agonist obesity treatments, so their combined or concurrent administration can enhance weight loss and improve side effects associated with long-term administration of GIP-1R agonist obesity treatments by improving weight loss plateaus, delaying the yo-yo effect, and improving lean body mass reduction.

This invention relates to the use of S100a8 / a9 and complement 3 inhibitors in the preparation of medicaments for the treatment or prevention of cachexia, wherein the treatment or prevention of cachexia involves increasing the body weight, lean body mass, fat mass, and food intake of cachectic subjects, or preventing fat loss, slowing the rate of weight loss, slowing the rate of fat mass loss, slowing the rate of lean body mass loss, resisting anorexia, resisting muscle weakness, resisting fatigue, resisting weight loss, and improving abnormal biochemical results. This invention provides a new understanding of the mechanism of energy balance regulation in cancer cachexia, focusing on the roles of S100a8 / a9 and C3 in cancer cachexia. This invention finds that inhibiting S100a8 / a9 and complement 3 can promote fat recovery and increase food intake. In particular, it demonstrates that S100a8 / a9 inhibitors can prevent the loss of body weight, especially adipose tissue, in cachectic subjects and significantly increase their food intake.

Applicant discloses methods and uses of the heteroaryl ketone fused azadecalin compound relacorilant for treating patients suffering from endogenous hypercortisolism (CS) (including Cushing's syndrome and Cushing's Disease) effective reduce or prevent the loss of tissue lean mass; in embodiments, the methods and uses are effective to increase tissue lean mass as compared to the patient's tissue lean mass prior to administration of relacorilant. The methods and uses of relacorilant for treating patients suffering from CS are further effective to reduce body weight and waist circumference of the patient.Therapeutic amounts of relacorilant may be between about 50 milligrams per day (mg / day) and up to about 800 mg / day, e.g., 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, or 500 mg / day. The treatments may be oral treatments, and relacorilant may be administered with food, or without food. Relacorilant is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure:

Disclosed herein are compositions and uses for healthy weight management by providing a consumable composition comprising N-trans-caffeoyltyramine and N-transferuloyltyramine. Some embodiments provide for glucose management in a subject. Some embodiments provided include, for example, the consumable composition capable of supporting abdominal fat loss, visceral fat loss, maintaining lean body mass, and supporting normal blood glucose regulation.

Applicant discloses methods and uses of the heteroaryl ketone fused azadecalin compound relacorilant for treating patients suffering from endogenous hypercortisolism (CS) (including Cushing's syndrome and Cushing's Disease) effective reduce or prevent the loss of tissue lean mass; in embodiments, the methods and uses are effective to increase tissue lean mass as compared to the patient's tissue lean mass prior to administration of relacorilant. The methods and uses of relacorilant for treating patients suffering from CS are further effective to reduce body weight and waist circumference of the patient. Therapeutic amounts of relacorilant may be between about 50 milligrams per day (mg / day) and up to about 800 mg / day, e.g., 100 mg / day, 200 mg / day, 300 mg / day, 400 mg / day, or 500 mg / day. The treatments may be oral treatments, and relacorilant may be administered with food, or without food. Relacorilant is (R)-(1-(4-fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridine-2-yl)methanone, which has the structure (A).

The present invention relates to use of a GLP-1R / GLP-2R dual agonist, namely dapiglutide, to reduce body fat or inhibit gain of body fat whilst preserving lean mass.

An electronic device obtains a target weight loss rate proportion of a user and a current weight of the user, where the target weight loss rate proportion is a weight loss rate proportion expected by the user, and the weight loss rate proportion is a proportion of a weight loss in first unit duration in the current weight. Fat loss content corresponding to the target weight loss rate proportion is determined, wherein the fat loss content is a ratio of fat amount in the reduced weight to the reduced weight. A calorie deficit of the user in second unit duration is determined based on the fat loss content corresponding to the target weight loss rate proportion, the target weight loss rate proportion, the current weight of the user, fat calories per unit weight, and lean body calories per unit weight.

This invention discloses a strain of *Lactobacillus delbrueckii* with muscle-protecting function during fat loss, its products, and applications, belonging to the field of microbial technology. The invention discloses *Lactobacillus delbrueckii* subspecies Turb8, with accession number CGMCC No. 35627. This strain or its preparations can effectively prevent or improve muscle loss and functional decline during the use of fat-loss drugs such as GLP-1 receptor agonists (e.g., liraglutide, smegglutide), achieving the effect of "fat loss without muscle loss." While maintaining the original weight-loss effect of fat-loss drugs, the strain of this invention can significantly increase the user's lean body mass percentage, increase lower limb muscle mass, increase muscle fiber cross-sectional area, and improve muscle function indicators such as limb strength and suspension endurance. This invention also relates to bacterial agents containing this strain, various preparations, and their application in the preparation of products for improving (especially drug-induced) muscle loss.